Pharmaceutical Technology

JANUARY 17, 2023

Nonetheless, patients receiving the current standard of care, Novo Nordisk’s Wegovy (injectable semaglutide), are expected to self-administer treatment on a weekly basis. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.

Development 130

Development Compliance Trials Marketing 130

XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). In the third quarter of 2022, Mounjaro scored $187.3

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

APRIL 29, 2022

The promising trial results could pose a threat to Danish drugmaker Novo Nordisk’s GLP-1 agonist drug Wegovy (semaglutide), which has dominated the obesity drug market since its launch in 2021. Related: Eli Lilly’s Type 2 Diabetes Shot Tirzepatide Emerges Winner Against Semaglutide.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Pharmaceutical Technology

NOVEMBER 30, 2022

Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. compared to a 5.1%

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. compared to a 5.1%

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246